NEW YORK – Seattle-based BrainChild Bio announced Friday that it is advancing its leading drug candidate, a CAR T-cell therapy targeting the immune checkpoint B7-H3 to a registrational trial, to ...

The biotech and hospital have expanded their collaboration, with Alcyone now advancing a gene therapy for Batten disease that the hospital was developing.

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

During a Q1 earnings call, Merck CEO Rob Davis discussed pipeline diversification plans and effects of tariffs on its ...

The subcutaneous Perjeta-Herceptin formulation, Phesgo, was a top driver of sales growth in the first quarter of 2025.

The firm reported a 6 percent decrease in Q1 2025 revenues to $11.2 billion compared to $11.87 billion last year.